70. Assessment of circulating tumor DNA tumor mutational burden to define resistance in HR+ HER2- metastatic breast cancer
2022; Elsevier BV; Volume: 268-269; Linguagem: Inglês
10.1016/j.cancergen.2022.10.073
ISSN2210-7770
AutoresAndrew A. Davis, Jingqin Luo, Tiantian Zheng, Xiaoxi Dong, T. Lu, Amy Wang, Rama Suresh, Foluso O. Ademuyiwa, Caron Rigden, Timothy P. Rearden, Katherine Clifton, Katherine N. Weilbaecher, Ashley Frith, Pavan K. Tandra, Tracy Summa, Britney Haas, Shana Thomas, Leonel F. Hernandez‐Aya, Lindsay L. Peterson, Dai Chao, Bonnie L. King, Pan Du, Shidong Jia, Jairam Krishnamurthy, X. Cynthia,
Tópico(s)PARP inhibition in cancer therapy
Referência(s)